| Literature DB >> 27822924 |
Hoang Viet Bach1, Jeongseon Kim1,2, Seung Kwon Myung1,2,3, Young Ae Cho2.
Abstract
We conducted a meta-analysis to investigate the efficacy of ginseng supplements on fatigue reduction and physical performance enhancement as reported by randomized controlled trials (RCTs). RCTs that investigated the efficacy of ginseng supplements on fatigue reduction and physical performance enhancement compared with placebos were included. The main outcome measures were fatigue reduction and physical performance enhancement. Out of 155 articles meeting initial criteria, 12 RCTs involving 630 participants (311 participants in the intervention group and 319 participants in the placebo group) were included in the final analysis. In the fixed-effect meta-analysis of four RCTs, there was a statistically significant efficacy of ginseng supplements on fatigue reduction (standardized mean difference, SMD = 0.34; 95% confidence interval [CI] = 0.16 to 0.52). However, ginseng supplements were not associated with physical performance enhancement in the fixed-effect meta-analysis of eight RCTs (SMD = -0.01; 95% CI = -0.29 to 0.27). We found that there was insufficient clinical evidence to support the use of ginseng supplements on reducing fatigue and enhancing physical performance because only few RCTs with a small sample size have been published so far. Further lager RCTs are required to confirm the efficacy of ginseng supplements on fatigue reduction.Entities:
Keywords: Fatigue; Ginseng Supplements; Meta-analysis; Physical Performance; Randomized Controlled Trial
Mesh:
Substances:
Year: 2016 PMID: 27822924 PMCID: PMC5102849 DOI: 10.3346/jkms.2016.31.12.1879
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Fig. 1Flow diagram for identification of relevant clinical trials.
General characteristics of studies in the final analysis (n = 12)
| No. | Source (project name) | Country location | Participants (follow-up period) | Intervention vs. Control | Type of ginseng | Main outcome measures used | Measurement tools | Mean ± SD (baseline/follow-up) | |
|---|---|---|---|---|---|---|---|---|---|
| Intervention | Placebo | ||||||||
| 1 | Engels 1996 | USA | 19 healthy adult females (8 wk) | 1,000 mg/day (n = 10) vs. placebo (n = 9) | Recovery oxygen uptake (VO2) | Incremental Bicycle Ergometer Exercise | 4 ± 0.2/3.9 ± 0.3 (ml/kg per min) | 4.1 ± 0.3/4 ± 0.2 (ml/kg per min) | |
| 2 | Engels 1997 | USA | 31 healthy adult males (8 wk) | 2,000 mg/day (n = 10) vs. 1,000 mg/day (n = 11) vs. Placebo (n = 10) | Maximal oxygen uptake (VO2 max) | Incremental Bicycle Ergometer Exercise | 42.3 ± 1.6/41.4 ± 1.5 (ml/kg per min) | 42.3 ± 3.1/42.9 ± 2.9 (ml/kg per min) | |
| 3 | Ziemba 1999 | Poland | 15 healthy people (6 wk) | 350 mg/day (n = 7) vs. placebo (n = 8) | Maximal oxygen uptake (VO2 max) | Incremental Bicycle Ergometer Exercise | 3.9 ± 0.09/3.8 ± 0.14 (l/min) | 3.8 ± 0.15/3.8 ± 0.15 (l/min) | |
| 4 | Engels 2001 | USA | 20 healthy women (8 wk) | 2,000 mg/day (n = 12) vs. placebo (n = 12) | Rate of fatigue | Wingate test | 47.89 ± 6.73/45.5 ± 8.4 | 47.68 ± 8.18/48.04 ± 6.31 | |
| 5 | Engels 2003 | USA | 27 healthy students (8 wk) | 2,000 mg/day (n = 15) vs. placebo (n = 12) | Mean power output | Wingate test | −0.13 ± 0.07 W/kg (Change score between before and after intervention) | −0.08 ± 0.08 W/kg (Change score between before and after intervention) | |
| 6 | Liang 2005 | USA | 29 healthy people (4 wk) | 1,350 mg/day (n = 13) vs. placebo (n = 16) | Exercise time to exhaustion (Tmax) | Incremental Bicycle Ergometer Exercise | 30.5 ± 12.8/37.6 ± 10.2 (mins) | 30 ± 12.6/33.6 ± 10.5 (mins) | |
| 7 | Kulaputana 2007 | Thailand | 57 health males (8 wk) | 500 mg/day (n = 28) vs. placebo (n = 29) | Total exercise time | Incremental Bicycle Ergometer Exercise | 18.6 ± 2.8/19.7 ± 2.6 (mins) | 17.2 ± 2.6/18.3 ± 2 (mins) | |
| 8 | Yoon 2008 | Korea | 14 healthy students (8 wk) | 3,000 mg/day (n = 10) vs. placebo (n = 10) | Oxygen uptake (VO2)/Maximal oxygen uptake (VO2 max) | Wingate test | 48.6 ± 2.3/50.1 ± 2.6 (%) | 48.5 ± 1.8/49.9 ± 2.7 (%) | |
| 9 | Kim 2011 | USA | 47 health participants (6 wk) | 100 mg/day in the 1st week, 200 mg/day in the 2nd week, 400 mg/day in the following 4 weeks for intervention group vs. placebo (Crossover study) | Fatigue score | Modified Fatigue Impact Scale | 47 ± 15/42.7 ± 15.7 | 47 ± 15/43.7 ± 16.7 | |
| 10 | Barton 2013 | USA | 271 men and women with cancer-related fatigue defined as a score of 4 or more (8 wk) | 2,000 mg of American ginseng/day (n = 183) vs. Placebo (n = 181) | The subjective experience of fatigue | The Multidimensional Fatigue Symptom Inventory–Short Form. | 20 ± 27 (Change score between before and after intervention) | 10.3 ± 26.1 (Change score between before and after intervention) | |
| 11 | Etemadifar 2013 | Iran | 52 female multiple sclerosis patients (12 wk) | 500 mg of Korean ginseng/day (n = 26) vs. Placebo (n = 26) | Fatigue score | Modified Fatigue Impact Scale | 31.69 ± 14.9/23.65 ± 12.8 | 22.23 ± 13.21/23.69 ± 12.94 | |
| 12 | Kim 2013 | Korea | 88 participants with idiopathic chronic fatigue (ICF) (4 wk) | 2,000 mg/day (n = 29) vs. 1,000 mg/day (n = 29) vs. Placebo (n = 30) | Fatigue severity | Numerical Rating Scale | 60.8 ± 10.3/41.8 ± 13.2 | 59.3 ± 10.6/48.8 ± 7.3 | |
Methodological quality of trials based on the Jadad scale (n = 12)
| No. | Study | Randomization | Description of randomization methods | Double-blind | Using identical placebo | Follow-up reporting | Total score |
|---|---|---|---|---|---|---|---|
| 1 | Engels et al. 1996 | 1 | 0 | 1 | 1 | 1 | 4 |
| 2 | Engels et al. 1997 | 1 | 1 | 1 | 1 | 1 | 5 |
| 3 | Ziemba et al. 1999 | 1 | 0 | 1 | 1 | 1 | 4 |
| 4 | Engels et al. 2001 | 1 | 0 | 1 | 1 | 1 | 4 |
| 5 | Engels et al. 2003 | 1 | 0 | 1 | 1 | 1 | 4 |
| 6 | Liang et al. 2005 | 1 | 1 | 1 | 1 | 1 | 5 |
| 7 | Kulaputana et al. 2007 | 1 | 0 | 1 | 1 | 1 | 4 |
| 8 | Yoon et al. 2008 | 0 | 0 | 1 | 1 | 1 | 3 |
| 9 | Kim et al. 2011 | 1 | 1 | 1 | 1 | 1 | 5 |
| 10 | Barton et al. 2013 | 1 | 1 | 1 | 1 | 1 | 5 |
| 11 | Etemadifar et al. 2013 | 1 | 1 | 1 | 1 | 1 | 5 |
| 12 | Kim et al. 2013 | 1 | 1 | 1 | 0 | 1 | 4 |
Fig. 2Efficacy of ginseng supplements on fatigue reduction in the meta-analysis of RCTs (n = 4).
Fig. 3Efficacy of ginseng supplements on physical performance enhancement in the meta-analysis of RCTs (n = 8).
Efficacy of ginseng supplements on fatigue reduction and physical performance enhancement in the subgroup meta-analysis of RCTs by various factors
| Factors | No. of Trials | SMD (95% CI) | Heterogeneity I2 (%) | Model used |
|---|---|---|---|---|
| Funding sources | ||||
| From companies | - | - | - | |
| From non-companies* | 4 | 0.34 (0.16–0.52) | 5.2 | Fixed-effects |
| Ginseng supplement sources | ||||
| From companies* | 2 | 0.28 (0.08–0.49) | 43.7 | Fixed-effects |
| From non-companies* | 2 | 0.54 (0.16–0.92) | 0 | Fixed-effects |
| Species of ginseng | ||||
| Korean ginseng* | 2 | 0.54 (0.16–0.92) | 0 | Fixed-effects |
| Non-Korean ginseng* | 2 | 0.28 (0.08–0.49) | 43.7 | Fixed-effects |
| Duration of intervention | ||||
| 1–6 wk | 2 | 0.28 (−0.23–0.80) | 59.3 | Random-effects |
| > 6 wk* | 2 | 0.39 (0.17–0.61) | 0 | Fixed-effects |
| Geographic location of studies | ||||
| Asian countries* | 2 | 0.54 (0.16–0.92) | 0 | Fixed-effects |
| Western countries* | 2 | 0.28 (0.08–0.49) | 43.7 | Fixed-effects |
| Dose of intervention | ||||
| < 1,000 mg/day | 2 | 0.20 (−0.12–0.53) | 40.5 | Fixed-effects |
| ≥ 1,000 mg/day* | 2 | 0.40 (0.18–0.62) | 0 | Fixed-effects |
| Funding resources | ||||
| From companies | 1 | −0.03 (−1.08–0.28) | - | Fixed-effects |
| From non-company | 7 | −0.01 (−0.30–0.28) | 0 | Fixed-effects |
| Ginseng supplement sources | ||||
| From companies | 3 | −0.08 (−0.29–0.31) | 0 | Fixed-effects |
| From non-companies | 5 | 0.06 (−0.34–0.47) | 0 | Fixed-effects |
| Species of ginseng | ||||
| Korean ginseng | 7 | 0.02 (−0.28–0.33) | 0 | Fixed-effects |
| Non-Korean ginseng | 1 | −0.21 (−0.95–0.52) | - | Fixed-effects |
| Duration of intervention | ||||
| 1–6 wk | 2 | 0.03 (−0.57–0.63) | 22.1 | Fixed-effects |
| > 6 wk | 6 | −0.02 (−0.34–0.29) | 0 | Fixed-effects |
| Geographic location of studies | ||||
| Asian countries | 2 | −0.01 (−0.47–0.46) | 0 | Fixed-effects |
| Western countries | 6 | −0.01 (−0.36–0.34) | 8 | Fixed-effects |
| Dose of intervention | ||||
| < 1,000 mg/day | 2 | 0.11 (−0.36–0.57) | 0 | Fixed-effects |
| ≥ 1,000 mg/day | 6 | −0.08 (−0.43–0.27) | 0 | Fixed-effects |
SMD = standardized mean difference, CI = confidence interval.
*Statistically significant association.